Symptomatic treatment

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

Retrieved on: 
星期三, 二月 14, 2024
PD, Newcastle University, Analyst, Research, University Medical Center, Internet, PI, Synucleinopathy, Biomarker, Therapy, Genetics, Task force, Columbia University, KOL, Symptomatic treatment, Pharmaceutical industry

“Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”

Key Points: 
  • “Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”
    GBA-associated Parkinson’s Disease & other Synucleinopathies: current unmet medical needs and needed therapies.
  • Discussion of recent in vivo data for GT-02287 as a best-in-class small molecule, for the treatment of GBA-Parkinson’s Disease and other neurodegenerative diseases.
  • His research interests are focused on the understanding of the molecular mechanisms of neurodegenerative diseases such as Parkinson’s, Huntington’s, and Alzheimer’s disease.
  • He is Chair of the Task Force on the Biological Definition of Parkinson’s Disease of Internation Parkinson and Movement Disorder Society.

Global Huntington's Disease Treatment Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
星期四, 九月 14, 2023
General Health, Science, Health, Research, HD, Huntington's disease, Drug development, Prevalence, Dysphagia, SRX246, HTT, Somnolence, Senior counsel, Disease, ZFP, Quality of life, Brain, Toxicity, II, Compound annual growth rate, Aggression, Investment, Patient, Palliative care, Growth, Irritation, Treatment, Symptomatic treatment, HRQOL, Pharmaceutical industry, Nursing, Vaccine

The "Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The anticipated growth of the global Huntington's disease treatment market is poised to make a significant impact, with projections indicating it will reach a substantial USD 1,871.2 million by 2030, as detailed in this comprehensive report.
  • Huntington's disease, a rare inherited neurodegenerative condition, exerts its impact across multiple generations, severely affecting individuals between the ages of 30 and 50.
  • The symptomatic treatment segment accounted for the largest revenue share in 2022 owing to the product availability and patent protection.

Global Huntington's Disease Treatment Market Size, Share & Trends Analysis Report 2022-2030, Featuring Profiles of H. Lundbeck, Teva Pharmaceutical, Bausch Health Companies and Lupin - ResearchAndMarkets.com

Retrieved on: 
星期五, 四月 29, 2022
Health, Pharmaceutical, USD, Huntington's disease, Patient, Investment, Topical steroid withdrawal, Apathy, ZFP, Somnolence, SRX246, Prevalence, Growth, Quality of life, Treatment, HD, Scope, Palliative care, Dysphagia, Neurodegeneration, CAGR, Chapter Three, Research, Disease, Brain, Irritation, Symptoms of COVID-19, Aggression, Symptomatic treatment, HTT, HRQOL, Medical device, Pharmaceutical industry, Vaccine

The "Huntington's Disease Treatment Market Size, Share & Trends Analysis Report by Treatment (Symptomatic Treatment, Disease-Modifying Therapies), by Region and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Huntington's Disease Treatment Market Size, Share & Trends Analysis Report by Treatment (Symptomatic Treatment, Disease-Modifying Therapies), by Region and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global Huntington's disease treatment market size is expected to reach USD 1.8 billion by 2030.
  • This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries.
  • The symptomatic treatment segment accounted for the largest revenue share in 2021 owing to the product availability and patent protection.